AzTrials
AzTrials

SpondylolisthesisPhase 2NCT01123850

CopiOs Posterolateral Fusion Procedure

A Phase 2 study testing Copios in people with Spondylolisthesis and Stenosis, run by Zimmer Biomet at 6 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

To compare radiographic data collection from patients undergoing instrumented PLF with CopiOs(R) BVF or instrumented PLF with autologous bone and to assess overall clinical outcomes. Patients will serve as self controls. Read more about this study

Who is it for?
Ages 21 to 85 years
Conditions the study is for
Spondylolisthesis, Stenosis
What is being tested?
Copios
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
6 sitesUnited States
Study dates
Jun 2010to Oct 2012
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient must be skeletally mature; between the ages of 21 and 75
  • Patients having degenerative spondylolisthesis, stenosis with instability, or degenerative disc disease as diagnosed by radicular signs and/or imaging studies
  • Patients will be medically indicated for a single-level, instrumented PLF between L2 and S1 per their surgeon
  • Patient must be willing and able to comply with study requirements, including all necessary study related paperwork and follow-up visits

Who cannot join

  • Use of iliac crest bone graft;
  • Any previous lumbar spinal surgeries at indicated level;
  • Any medical or physical condition that would preclude the potential benefit of spinal surgery;
  • Use of a dynamic stabilization systems;
  • Sites where stresses on void will exceed the load strength of fixation of hardware;
  • Segmental defects;
Show all 21Show fewer
  • Significantly impaired vascularity proximal to the surgical site;
  • Sites in direct contact with articular space;
  • Soft tissue deficit not allowing closure;
  • Active systemic or local infection;
  • Severe degenerative bone disease;
  • Patients with osteoporosis who are actively under treatment;
  • Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI>40 kg/m2);
  • Active malignancy;
  • Patients with a history of multiple allergies;
  • Patients with known allergies to bovine collagen;
  • Hypercalcemia;
  • Pregnancy;
  • Mental illness;
  • Alcohol or drug abuse;
  • Incarceration.

Trial locations and contacts

6 sites in 1 country.

6 sites in 1 country

United States6 sites
  • Neurological Surgery of Southern Illinois

    Belleville, Illinois, 62226

  • Upstate Bone and Joint Center

    East Syracuse, New York, 13057

  • Indiana Orthopedic Center

    Indianapolis, Indiana, 46250

  • Las Cruces Orthopaedic Associates

    Las Cruces, New Mexico, 88005

  • Florida Hospital

    Orlando, Florida, 32803

  • Scott and White Healthcare

    Temple, Texas, 76508

Other trials in United States

About this study

Official title: A Prospective Study Assessing Clinical Outcomes and Radiographic Results After the Use of CopiOs(R) Bone Void Filler (BVF)Sponge in a Posterolateral Fusion Procedure (PLF).

To compare radiographic data collection from patients undergoing instrumented PLF with CopiOs(R) BVF or instrumented PLF with autologous bone and to assess overall clinical outcomes. Patients will serve as self controls.

Read the detailed description

This is a prospective, counter-balanced study involving 85 subjects at up to 8 investigative centers. Each subject will be an appropriate candidate for an instrumented PLF and will meet the inclusion and exclusion criteria. All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study. Data will be collected pre-operatively, operatively and post-operatively at six and twelve months.

The study objectives include: Radiographic success of CopiOs is non-inferior to autograft with clear evidence of bridging bone. Radiographic analysis will be used to show that CopiOs works as well as autograft when comparing the rate of fusion at 6 and 12 months. The CT scan (12 month) will show that CopiOs works as well as autograft when comparing the fusion mass between the transverse processes. Additionally, clinical success will be determined by an improvement of 15 percentage points using the Oswestry Disability Index and maintenance or improvement in the motor and sensory components of the neurological assessment from preoperative to postoperative. Since patients serve as self-controls there will be no clinical success comparisons between the groups. Rather, clinical success will be measured on overall improvement based on patient outcomes.

Being tested
Copios
Keywords
CopiOs, Degenerative spondylolisthesis,, stenosis with instability, or, degenerative disc disease as diagnosed by radicular signs and/or imaging studies
Medical subject headings
Spondylolisthesis, Constriction, Pathologic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CopiosDevice

    Bone Void Filler

Study groups in NCT01123850
Study groupRoleWhat they receive
Single ARM - Copios Bone FillerActive comparatorAll subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study.
Receives: Device: Copios

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fusion Assessment

    Fusion at 12M using radiograph Fusion Mass at 12M using CT

    Measured: 6 M, 12 M

Secondary outcomes (1)
  1. Outcome Measure - Pain, Life Quality, Satisfaction

    Measured: PreOp, Surgery, 6M, 12M

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2010 (estimated)
  2. Study startJun 2010
  3. Primary completionOct 2012
  4. Study completionOct 2012

Why it stopped: Slow enrollment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
45 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01123850
Sponsor's protocol ID
2008-001
Status last verified
May 2015
First submitted
12 May 2010
Last updated
27 May 2015
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Copios in people with Spondylolisthesis and Stenosis, run by Zimmer Biomet at 6 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 27 May 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 May 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fusion Assessment (time frame: 6 M, 12 M). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2015.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in